Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Acumen Pharmaceuticals Inc. Common Stock
ABOS | US
2.70
USD-0.16
-5.59%
ABOS | US
About Acumen Pharmaceuticals Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.70
Open
2.85
High
2.95
Low
2.64
Acumen Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193 a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Charlottesville Virginia.
View LessABOS | US
Risk
68.6
Sharpe
-0.43
Luna's Score
52/100
Recommendation
Hold
Luna says (ABOS | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
77.3%1 month
68.6%3 months
80.6%6 months
75.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.66
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
-0.60
Ent. to rev.
89.67
PEG
-
Other Fundamentals
EBITDA
-76.61M
MarketCap
162.22M
MarketCap(USD)
162.22M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-31.43
Short ratio
8.91
Short perc.
3.49
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.74
Range1M
0.74
Range3M
1.45
Volumes: Market Activity
Rel. volume
0.94
Price X volume
488.49K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.60 | - | Cheaper |
| Ent. to Revenue | 89.67 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.66 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 80.56 | - | Par |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 162.22M | - | Emerging |
